RECRUITING Not applicable ClinicalTrials.gov

Anti-inflammatory Effects of Curcumin, Ginger and Piperine Supplementation in Ultra-trail Runners: a Double-blind Randomized Placebo-controlled Trial

Sponsor: Centre Hospitalier Universitaire de la Réunion • ClinicalTrials.gov ID: NCT07699575

Registry updated: 2026-09-22

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

ECUM-RUN is a randomized, double-blind, placebo-controlled phase 3 trial evaluating whether a 30-day oral supplementation with curcumin, ginger, and piperine (9-5-1 formulation) reduces exercise-induced joint pain and inflammatory markers in 82 ultra-trail runners competing in the Diagonale des Fous (175 km). The primary endpoint is the change in knee pain (VAS score) between end of supplementation and race finish, compared between intervention and placebo groups.

Interventions

9-5-1 (Dietary supplement)
The investigational intervention is an oral food-supplement capsule combining curcumin, ginger, and piperine in a proprietary "9-5-1" ratio (curcuma extract : ginger extract : black pepper/piperine extract), administered as 4 capsules per day for 30 consecutive days prior to the race.
Placebo (Dietary supplement)
Capsule excipients are maltodextrin and hydroxypropylmethylcellulose (HPMC), allowing an identical-appearing placebo for double-blind conditions.

Eligibility criteria

Inclusion Criteria: * Age ≥ 18 years at inclusion * Registered for "La Diagonale des Fous" (Grand Raid de La Réunion, 175 km, 2026 edition) * Free, informed, signed consent obtained prior to any study-related procedure * Availability to participate in the full protocol, including preliminary consultations and biological sampling at all time points (T0 to T3) * Affiliated with or beneficiary of a social security scheme * Ability to understand and follow study instructions (sufficient French language level, or assistance available) Exclusion Criteria: * Regular NSAID use in the 30 days prior to inclusion, defined as intake at least 3 days/week for at least 2 consecutive weeks, or ongoing treatment at the time of inclusion * Regular use of curcumin-containing supplements or "9-5-1"-type preparations in the 30 days prior to inclusion, defined as intake at least 3 days/week for at least 2 consecutive weeks * Taking anticoagulant treatment * History of hepatic, biliary, or pancreatic disease, including: gallstones, cholestasis, acute or chronic hepatitis, cirrhosis * Known allergy or documented hypersensitivity to any capsule component: turmeric, curcumin, ginger, black pepper, maltodextrin, or hydroxypropylmethylcellulose (HPMC) * Chronic inflammatory joint disease (e.g., rheumatoid arthritis, spondyloarthritis) under active specific treatment * Pregnancy or breastfeeding * Participation in another biomedical study involving a therapeutic intervention within the 30 days prior to inclusion * Severe cognitive or psychiatric impairment preventing understanding of the protocol or completion of questionnaires * Patient under guardianship/curatorship or subject to a legal protection order

Conditions

Joint Pains

Locations

Dr Nicolas BOUSCAREN — Saint-Pierre, CHU de La Réunion, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment